Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Overview
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule Inc
AstraZeneca Plc
Bayer AG
Cotinga Pharmaceuticals Inc
Laek Therapeutics Shanghai Co Ltd
Merck & Co Inc
Novartis AG
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Drug Profiles
ARQ-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1125976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capivasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COTI-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Dormant Products
RAC Beta Serine/Threonine Protein Kise (Protein Kise Akt 2 or Protein Kise B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: ArQule presents recent data on ARQ 751 at the 2019 AACR-NCI-EORTC Intertiol Conference on Molecular Targets and Cancer Therapeutics
Oct 21, 2019: ArQule announces preclinical data demonstrating potential of Miransertib (ARQ 092) to treat PIK3CA-driven vascular malformations at 2019 ASHG Annual Meeting
Oct 16, 2019: ArQule announces presentations on ARQ 751 at the 2019 AACR-NCI-EORTC Intertiol Conference on Molecular Targets and Cancer Therapeutics
Oct 08, 2019: ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
Oct 02, 2019: ArQule announces first patient dosed in registratiol MOSIAC trial of Miransertib for the treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
Jul 18, 2019: Cotinga Pharmaceuticals releases additiol interim data of phase 1b/2a combition trial of COTI-2 in solid tumors
Jun 27, 2019: Cotinga Pharmaceuticals doses first patient in third cohort of phase 1b/2a combition trial of COTI-2 in Solid Tumors
Jun 17, 2019: ArQule announces prelimiry results from its phase 1/2 study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference
Jun 10, 2019: ArQule announces oral presentation for its Pan-AKT inhibitor, miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
Jun 05, 2019: Cotinga Pharmaceuticals announces initiation of next cohort of phase 1b/2a combition trial of COTI-2 in solid tumors
May 08, 2019: Cotinga Pharmaceuticals releases early interim data of phase 1b/2a combition trial of COTI-2 in solid tumors
Mar 19, 2019: Cotinga Pharmacueticals provides scientific and business update at annual general meeting and announces unit offering
Feb 26, 2019: Cotinga Pharmaceuticals doses first patient in second cohort of phase 1b/2a combition trial of COTI-2 in Solid Tumors
Feb 25, 2019: ArQule announces publication of clinical data with Miransertib in Proteus syndrome
Jan 29, 2019: Cotinga Pharmaceuticals doses cohort 1 patients with combition therapy in phase 1b/2a trial of COTI-2
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Route of Administration, H2 2019
Number of Products by Molecule Type, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by ArQule Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019